Triple-negative breast cancer: transcriptomics improves prediction of treatment response

New data from the NeoTRIPaPDL1 phase III trial show that longitudinal gene expression profiling, tracking tumors over time, can identify early markers of response to neoadjuvant chemoimmunotherapy